Previous Close | 2.1000 |
Open | 2.1000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 2.1000 - 2.1000 |
52 Week Range | 2.1000 - 11.2500 |
Volume | |
Avg. Volume | 2 |
Market Cap | 52.68M |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1080 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LYON, France, May 13, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21st, 2022 at 9 am CEST at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON.
LYON, France, May 04, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2021 has been filed with the French market authority (Autorité des Marchés Financiers, or AMF).
LYON, France, April 25, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that the Poxel team will participate in several upcoming scientific conferences in May 2022.